Skip to main content
. Author manuscript; available in PMC: 2022 Aug 15.
Published in final edited form as: J Acquir Immune Defic Syndr. 2021 Aug 15;87(5):1145–1153. doi: 10.1097/QAI.0000000000002712

Table 3.

Characteristics of HIV-Negative Individuals at Each Stage of the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum1 Compared to Individuals Newly Diagnosed with HIV, Baltimore, Maryland September 30, 2015 – September 29, 2019

Reported New HIV Diagnoses
2016–20182 		PrEP Care Continuum Outcomes
Screened Indicated Referred Linked Clinically Evaluated Prescribed
N = 764 N = 25,886 N = 8,063 N = 4,578 N = 1,250 N = 868 N = 722
n % n % n % n % n % n % n %
Race/Ethnicity
Non-Hispanic Black 613 80.2 20,998 81.1 5,875 72.9 ‡ 3,080 67.2 ‡ 766 61.3 ‡ 593 68.3 ‡ 392 54.3 ‡
Non-Hispanic White 82 10.7 2,708 10.5 1,436 17.8 996 21.8 339 27.1 254 29.3 226 31.3
Hispanic 48 6.3 1,464 5.7 446 5.5 281 6.1 81 6.5 69 7.9 55 7.6
Non-Hispanic Other 21 2.8 716 2.8 306 3.8 221 4.8 73 5.8 51 5.9 49 6.8
Age
13–24 years 162 21.2 7,600 29.4 ‡ 2,302 28.6 ‡ 1,355 29.6 ‡ 381 30.5 ‡ 259 29.8 ‡ 46 26.9 ‡
25–34 years 265 34.7 9,141 35.3 2,857 35.4 1,602 35.0 512 41.0 375 43.2 355 45.6
≥ 35 years 337 44.1 9,145 35.3 2,904 36.0 1,621 35.4 357 28.6 234 27.0 201 27.6
Gender
Cisgender males 570 74.6 15,825 61.1 ‡ 5,587 69.3 2,820 61.6 ‡ 958 76.6 692 79.7 ‡ 606 83.9 ‡
Cisgender females 179 23.4 9,713 37.5 2,128 26.4 1,572 34.3 215 17.2 137 15.8 87 12.0
Transgender4 15 2.0 348 1.3 348 4.3 186 2.3 77 6.2 39 4.5 29 4.0
Priority Populations 3
MSM4 358 55.2 2,870 11.1 ‡ 2,870 35.6 ‡ 1,684 36.8 ‡ 787 63.0 ‡ 590 68.0 ‡ 538 74.5 ‡
MSM PWID4 12 1.8 20 0.1 20 0.2 15 0.3 7 0.6 < 55 < 0.6 < 55 < 0.7
Transgender4 15 2.3 348 1.3 348 4.3 186 4.1 77 6.2 39 4.5 29 4.0
PWID4 65 10.0 196 0.8 196 2.4 66 1.4 11 0.9 6 0.7 < 55 < 0.7
Heterosexual 199 30.7 22,452 86.7 4,629 57.4 2,627 57.4 638 51.0 231 26.6 150 20.8
1

PrEP care continuum outcome definitions:

Screened: received HIV screening and/or assessed for HIV acquisition risk.

Indicated: based on U.S. Centers for Disease Control PrEP guidelines and local epidemiology and includes individuals who: were cisgender gay, bisexual or other man who has sex with men (MSM); were transgender; or reported needle sharing (past 12m), a sex partner living with HIV (past 12m), buying or selling sex (past 12m), ≥ 2 episodes of HIV post-exposure prophylaxis (past 12m), previous syphilis, gonorrhea or rectal chlamydia diagnosis (past 3m).

Referred: received information on how to obtain PrEP and/or direct referral to a PrEP provider.

Linked: received navigation and/or clinical services related to PrEP at a participating site.

Clinically Evaluated: received a clinical exam for PrEP at a participating site.

Prescribed: PrEP prescription documented.

2

Baltimore City residents with a new HIV diagnosis reported between January 1, 2016 and December 31, 2018

3

Excludes 116 individuals newly diagnosed with HIV with no priority population identified. The total number of individuals newly diagnosed with HIV with assigned priority population is 648.

4

Transgender: individuals whose gender identity differs from their sex assigned at birth; MSM: gay, bisexual or other man who has sex with men; PWID: persons who inject drugs

5

Data suppressed

‡

p < 0.001